- Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
- Serotonin reuptake inhibitors
- Sympathomimetic-GABA receptor agonists
- Sympathomimetics
- Others
Obesity Treatment Market size was valued at USD 752.6 million in 2022 and is poised to grow at a CAGR of 16.7% from 2023-2029. Obesity is a medical condition that occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to the World Health Organization, more than 30 people are obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications. Obesity treatment reduces body mass either by an increase in calorie consumption or by a decrease in craving. The global Obesity Treatment Market is expected to grow at a significant CAGR owing to an increase in the R&D activities for the innovation of new products and the presence of various pipeline products for the treatment of obesity. The increase in the prevalence of the obese population fuelling the obesity treatment market growth. According to the World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, the entry of generic products due to the patent expiry of blockbuster treatments also drives the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk received European Commission marketing authorization approval for Saxenda an injectable obesity drug, and launched the same in the Indian market in 2017.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence of obese population around the globe, increase in R&D activities for the innovation of new treatment, change in lifestyle such as food habits, and genetic inheritance is the major factors anticipated fuel the obesity treatment market over the forecast period. Moreover, increase in awareness about obesity treatment, huge pipeline products available for the obesity treatment, and government initiations for increasing awareness about chronic nature of obesity are propelling the obesity treatment market. However, high cost for R&D activities, alternative treatment for the obesity, adverse effects associated with the treatment, and stringent regulatory guidelines might hinder the growth of Obesity Treatment Market.
The obesity treatment market is projected to expand at a CAGR of 16.7% during the forecast period
Boehringer Ingelheim GmbH, Novo Nordisk A/S, GlaxoSmithKline Plc, AstraZeneca Plc, F. Hoffmann La Roche Ltd.
North-America is the fastest-growing region for obesity treatment market
1.Executive Summary |
2.Global Obesity Treatment Market Introduction |
2.1.Global Obesity Treatment Market - Taxonomy |
2.2.Global Obesity Treatment Market - Definitions |
2.2.1. By Action |
2.2.2. By Route Administration |
2.2.3. By Distribution Channel |
2.2.4. By Region |
3.Global Obesity Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Obesity Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Obesity Treatment Market By Action, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Serotonin reuptake inhibitors |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Sympathomimetic-GABA receptor agonists |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Sympathomimetics |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Obesity Treatment Market By Route Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Injectables |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Obesity Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Hospital pharmacies |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail pharmacies |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online pharmacies |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Obesity Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
9.1.2.Serotonin reuptake inhibitors |
9.1.3.Sympathomimetic-GABA receptor agonists |
9.1.4.Sympathomimetics |
9.1.5.Others |
9.2. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Injectables |
9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital pharmacies |
9.3.2.Retail pharmacies |
9.3.3.Online pharmacies |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
10.1.2.Serotonin reuptake inhibitors |
10.1.3.Sympathomimetic-GABA receptor agonists |
10.1.4.Sympathomimetics |
10.1.5.Others |
10.2. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Injectables |
10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital pharmacies |
10.3.2.Retail pharmacies |
10.3.3.Online pharmacies |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
11.1.2.Serotonin reuptake inhibitors |
11.1.3.Sympathomimetic-GABA receptor agonists |
11.1.4.Sympathomimetics |
11.1.5.Others |
11.2. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Injectables |
11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital pharmacies |
11.3.2.Retail pharmacies |
11.3.3.Online pharmacies |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
12.1.2.Serotonin reuptake inhibitors |
12.1.3.Sympathomimetic-GABA receptor agonists |
12.1.4.Sympathomimetics |
12.1.5.Others |
12.2. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Injectables |
12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital pharmacies |
12.3.2.Retail pharmacies |
12.3.3.Online pharmacies |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
13.1.2.Serotonin reuptake inhibitors |
13.1.3.Sympathomimetic-GABA receptor agonists |
13.1.4.Sympathomimetics |
13.1.5.Others |
13.2. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Injectables |
13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital pharmacies |
13.3.2.Retail pharmacies |
13.3.3.Online pharmacies |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Boehringer Ingelheim GmbH (Germany) |
14.2.2.Takeda Pharmaceuticals co. Ltd. (Japan) |
14.2.3.Novo Nordisk A/S (Denmark) |
14.2.4.GlaxoSmithKline Plc (U.K.) |
14.2.5.AstraZeneca Plc (U.K.) |
14.2.6.F. Hoffmann La Roche Ltd. (Switzerland) |
14.2.8.Gubra (Denmark) |
14.2.9.Orexigen Therapeutics Inc. (U.S.) |
14.2.10.Eisai Co. Ltd. (Japan) |
15. Research Methodology |
16. Appendix and Abbreviations |